Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation Riluzole after Ketamine in MDD
NCT00419003Phase 4Completed
- Sponsor
- Baylor College of Medicine
- Start
- Dec 2006
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of riluzole in major depressive disorder (MDD) (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 24 hours. Started Dec 2006; status: completed.
02
Drugs
riluzole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00419003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00419003.